The Oculis strategy is to build a specialty ophthalmology company unlike any other. Our plan is to:
Our most advanced product candidate based on SNP technology is OCS-01, which is in clinical trials in patients with DME and in planning phase for potential front-of-the-eye indications.
If approved in DME, it has the potential to provide a new option for patients for whose current therapies are limited to intravitreal injections or implants.
Our novel technology provides an unprecedented technical advancement in ocular drug delivery, particularly for back-of-the-eye diseases that are currently managed by invasive methods such as intraocular injections or implants.